ROBIN SHERRINGTON 4
4 · Xenon Pharmaceuticals Inc. · Filed Mar 8, 2024
Insider Transaction Report
Form 4
ROBIN SHERRINGTON
See Remarks
Transactions
- Sale
Common Shares
2024-03-07$46.30/sh−6,118$283,263→ 8,398 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-07−1,234→ 0 totalExercise: $9.85Exp: 2024-03-11→ Common Shares (1,234 underlying) - Sale
Common Shares
2024-03-07$46.15/sh−1,019$47,027→ 14,516 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-07−7,407→ 0 totalExercise: $9.85Exp: 2024-03-11→ Common Shares (7,407 underlying) - Tax Payment
Common Shares
2024-03-07$45.96/sh−1,289$59,242→ 15,535 total - Exercise/Conversion
Common Shares
2024-03-07$9.85/sh+1,234$12,155→ 9,632 total - Tax Payment
Common Shares
2024-03-07$45.96/sh−215$9,881→ 9,417 total - Exercise/Conversion
Common Shares
2024-03-07$9.85/sh+7,407$72,959→ 16,824 total
Footnotes (5)
- [F1]The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
- [F2]Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations.
- [F3]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.15 to $46.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.25 to $46.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F5]The shares subject to this option are fully vested and exercisable.